Allurion Technologies, Inc. develops and commercializes a non-surgical weight-loss solution centered on the Allurion Balloon (also referred to as the Allurion Smart Capsule) and a supporting digital care platform. The company sells balloons to distributors and directly to healthcare providers, who use the product as part of the broader Allurion Program that includes remote patient support and monitoring tools. Allurion operates as a single reporting segment and is focused on expanding provider adoption and geographic reach while pursuing regulatory approvals, including a U.S. FDA premarket application for the Allurion Program. The company is also positioning its Virtual Care Suite (VCS) as a follow-up platform that can support patients using other weight-loss interventions such as anti-obesity medications and bariatric surgery.
−191,6 %
62,8 %
−188,8 %
−52,6 %
0.33
0.26
| % | |
|---|---|
| Allurion Balloon device sales | 85% Sales of the Allurion Balloon to distributors and healthcare providers for patient treatment. |
| Digital care platform (VCS) and software-enabled services | 10% Virtual Care Suite and related remote monitoring, onboarding, and treatment tracking tools used by clinics and patients. |
| Training, marketing, and program enablement | 5% Clinic enablement activities tied to adoption, including training events and program support bundled with commercialization. |
Allurion’s direct customers are distributors and healthcare providers that purchase the Allurion Balloon for use in...
Purchase the Allurion Balloon and use the Allurion Program and remote monitoring tools to deliver a non-surgical weight-loss intervention and manage patients over time.
Buy balloons for resale and commercialization in international markets, providing local market access and sales coverage.
Adopt the Virtual Care Suite to onboard and track patients using anti-obesity medications and bariatric surgery, expanding the platform beyond balloon patients.
Allurion’s Allurion Program products are currently sold across Europe, the Middle East, Africa, Latin America, Canada,...
Allurion’s near-term strategy emphasizes driving broader provider adoption of the Allurion Balloon by increasing...
Revenue growth depends on broader provider awareness, demand generation, and increased frequency of use.
Sales growth requires timely approvals and maintaining regulatory clearance, including U.S. entry via FDA review.
A broader software platform could extend engagement beyond balloon patients and create additional adoption pathways with providers.
Restructuring is intended to reduce costs, but execution must avoid disrupting commercialization, R&D, and compliance.
Allurion’s growth is highly sensitive to market acceptance by healthcare providers, since demand depends on provider...
Growth depends on obtaining and maintaining approvals and successfully implementing any remediation required by regulators to resume sales of the Allurion Balloon.
The company expects one-time severance costs and may face delays, unexpected costs, and reduced ability to implement strategy or retain employees.
Workforce reductions and constrained resources can weaken infrastructure, legal/regulatory compliance, R&D and clinical trial activities, and security controls.
ACON · Services-Medical Laboratories
XAIR · Surgical & Medical Instruments & Apparatus
SENS · Industrial Instruments For Measurement, Display, and Control
TCRT · Pharmaceutical Preparations
INGR · Grain Mill Products
Ingredion converts corn, tapioca, potato, rice, fruits and other plant-based inputs into starches, sweeteners and specialty ingredient systems used by food,…
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
: 11/08/2026